Immune Regulation Limited, a US and UK-based clinical-stage biotechnology company, announced on Monday that it has closed a Series B round of financing led by Boston-based Morningside Ventures, a part of Hong Kong’s Chan family-owned Morningside Group.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in